| Trial ID: | L2700 |
| Source ID: | NCT06739044
|
| Associated Drug: |
Ozempic®
|
| Title: |
Efficacy and Safety of Semaglutide Injection Vs Ozempic® in Patients with Type 2 Diabetes
|
| Acronym: |
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Ozempic®|DRUG: HDG1901
|
| Outcome Measures: |
Primary: Change in HbA1c from baseline, Week 32 | Secondary: Change in HbA1c from baseline, Week 20|Change in Fasting Plasma Glucose(FPG) from baseline, Week 20， Week 32|HbA1c ≤ 6.5%, Week 20, Week 32|HbA1c ≤ 7.0%, Week 20，Week 32|C-peptide, Week 20, Week 32|Insulin, Week 20, Week 32
|
| Sponsor/Collaborators: |
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
494
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-09-20
|
| Completion Date: |
2025-02-10
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-18
|
| Locations: |
Beijing Hospital, Beijing, Beijing, China
|
| URL: |
https://clinicaltrials.gov/show/NCT06739044
|
